>>NCT01800214
Patient Inclusion Criteria ( General ):.
 - Age between 40 and 90 ( inclusive ).
 - Fluent in English.
 - Completed six grades of education or higher.
 - Visual and auditory acuity adequate for neuropsychological testing.
 - Mini-Mental State Exam ( MMSE ) score > 10.
 Patient Exclusion Criteria ( General ):.
 - Possible secondary causes of dementia, concomitant or history of neurological or psychiatric illness ( other than stroke or Parkinsonism ).
 - History of alcohol or substance abuse or dependence within the past 2 years.
 Normal Control Inclusion Criteria :.
 - Age between 50 - 90.
 - Fluent in English.
 - Completed six grades of education or higher.
 - No significant memory complaints.
 - Mini-Mental State Exam ( MMSE )  > 24.
 Normal Control Exclusion Criteria :.
 - Being treated or history of being treated for psychiatric or neurological illness.
 - History of alcohol or substance abuse or dependence within the past 2 years.
 - Current use of psychoactive medications ( e.g. antidepressant, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.).
 - Medical contraindications to MRI.

>>NCT02322021
Inclusion criteria :.
 Subjects must meet all of the following criteria to be included in this study :.
 1. Meets the core clinical research criteria of the NIA-AA for MCI due to AD ( which is consistent with Prodromal AD ) or AD dementia and is 'staged' or classified as either MCI or mild to moderate dementia.
 2. Amyloid positive Positron Emission Tomography ( PET ) image based on centralized PET scan reading.
 3. Male or female, age 50 to 85 years, inclusive at time of consent.
 4. Must have an identified caregiver or informant who is willing and able to provide follow-up information on the subject throughout the course of the study.
 5. If receiving an Acetylcholinesterase Inhibitor ( AChEI ) or memantine, must have been on a stable dose for at least 12 weeks before the Baseline cognitive assessments, with no plans for dose adjustment in the foreseeable future. Treatment-naive subjects can be entered into the study but there should be no plans to initiate treatment with AChEIs or memantine at the time of entry into the study.
 6. Must have been on stable doses of all other permitted chronically used concomitant medications ( ie, not related to their cognitive decline ) for at least 4 weeks before randomization.
 Exclusion criteria :.
 Subjects who meet any of the following criteria will be excluded from this study :.
 1. Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the subject's AD pathology, including any co-morbidities such as cerebrovascular disease, detected by medical history, neurological examination or MRI.
 2. History of transient ischemic attacks or stroke within 12 months of Screening.
 3. History of epilepsy.
 4. Evidence of depression on a rating scale at Screening or any psychiatric diagnosis or symptoms, ( eg, hallucinations, major depression, etc.) that could confound the diagnosis or could interfere with study assessments or procedures. This includes suicidal ideation or suicidal behavior within 6 months prior to Screening or hospitalization or treatment for suicidal behavior in the past 5 years.
 5. Abnormally low serum vitamin B12.
 6. Thyroid stimulating hormone above the normal range. This applies to all subjects regardless of whether or not they are taking thyroid supplements.
 7. Subjects with liver disease ( hepatic impairment ), at Screening or Baseline. Subjects with Gilbert's syndrome need not be excluded.
 8. Not able to have a MRI, PET scanning or CSF collection by Lumbar Puncture ( LP ).
 9. Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
 10. History of immunodeficiency disorders.
 11. Subjects with chronic viral hepatitis.
 12. History of Tuberculosis ( TB ). Subjects with no history of TB will be tested for previous TB exposure and a positive test will be exclusionary.
 13. History of ophthalmic shingles or ocular Herpes Simplex Virus ( HSV ) infection.
 14. Any live vaccine in the 3 months or any active infection within the last 4 weeks before study drug administration ( i.e. randomization ).
 15. Any chronic inflammatory disease that is not adequately controlled or requires immunosuppressive or immunomodulatory therapy.
 16. T helper cell, cytotoxic T cell or B cell absolute counts below normal.
 17. Immunoglobulin ( Ig ) IgG, IgA or IgM levels below normal at Screening or Baseline, unless both the Investigator and the Medical Monitor agree that the finding is not clinically significant.
 18. Clinically significant deviation from normal in physical examination, vital signs or clinical laboratory tests at Screening or Baseline.
 19. Exclusionary cardiac factors include : prolonged QT interval greater than 450 msec from Electrocardiograms ( ECGs ); history of risk factors for torsade de pointes or the use of concomitant medications that prolong the QT/QTc interval; left bundle branch block; persistent low or high heart rate; persistent low or high blood pressure; history of cardiac arrhythmias; other clinically significant ECG abnormalities.
 20. Type 1 or Type 2 diabetes mellitus that is not well controlled.
 21. Malignant neoplasms within 5 years before Screening ( except for basal or squamous cell carcinoma in situ of the skin or localized prostate cancer that did not require systemic therapy; these do not exclude the subject ).
 22. Medical conditions ( eg, cardiac, respiratory, gastrointestinal, renal disease ) that are not stably controlled or which, in the opinion of the investigator ( s ), could affect the subject's safety or interfere with the study assessments.
 23. Hypopigmentation conditions ( eg, albinism and vitiligo ).
 24. Known or suspected history of drug or alcohol dependency or abuse within 2 years, current use of recreational drugs or a positive urine drug test.
 25. Planned surgery that requires general, spinal or epidural anesthesia that would take place during the study.
 26. Participation in any other interventional clinical study related to cognitive impairment within 6 months before Screening unless it can be documented that the subject was in a placebo treatment arm.
 27. Currently enrolled in another clinical study or used any investigational drug or device within 60 days or 5 half-lives of the investigational medication ( whichever is longer ) proceeding informed consent.
 28. Hypersensitivity to the study drug or any of the excipients or to other Beta Secretase Cleaving Enzyme ( BACE ) inhibitors or to the PET tracer or components of its formulation.
 29. Females who are lactating or pregnant. Females of childbearing potential who do not agree to adhere to the protocol specified methods for avoiding pregnancy.
 30. Males who do not meet the protocol requirements for avoiding their partners becoming pregnant. Sperm donation is not permitted.

>>NCT01862640
Inclusion Criteria :.
 - Male and female subjects 55 to 90 years of age, inclusive, at the time of informed consent.
 - Subjects who are residing either in an institutionalized setting ( e.g., dementia unit, nursing home, assisted living facility or other residential care facility ) or in a non-institutionalized setting where the subject is not living alone. Subjects must have been at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the trial.
 - Subjects with a diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA.
 - Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.
 - Subjects with onset of symptoms of agitation at least 2 weeks prior to the screening visit.
 - Subjects with a score of >= 4 on the agitation/aggression item of the NPI-NH at the screening and baseline visits.
 - Subjects who require pharmacotherapy for treatment of agitation per the investigator's judgment, after an evaluation for reversible factors ( eg, pain, infection, polypharmacy ) and a trial of nonpharmacological intervention.
 - Subjects must have a previous MRI or CT scan of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.
 Exclusion Criteria :.
 - Subjects with dementia or other memory impairment not due to Alzheimer's disease.
 - Subjects with a history of stroke, well-documented transient ischemic attack, pulmonary or cerebral embolism.
 - Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal or psychiatric disorders.
 - Subjects who have been diagnosed with an Axis I disorder ( DSM-IV-TR criteria ).
 - Subjects with uncontrolled hypertension.
 - Subjects with uncontrolled insulin-dependent diabetes mellitus ( IDDM ).
 - Subjects with epilepsy or a history of seizures.
 - Subjects considered in poor general health based on the investigator's judgment.

>>NCT00675090
Inclusion Criteria :.
 - Male or female subjects with a clinical diagnosis of probable Alzheimer's disease.
 - The subject has an MMSE score at screening of 12 to 26 for Part A and 16 - 26 for Part B.
 - Age >= 50 and above.
 - If female, the subject must be post-menopausal ( i.e. 12 months without menstrual period ) or surgically sterile.
 - Male subjects must be willing to abstain from sexual intercourse with pregnant or lactating women; or be willing to use a condom/spermicide in addition to having their female partner use another form of contraception if the woman could become pregnant, from the time of the first dose of GSK239512 until 84 days following completion of the study.
 - The subject has the ability to comply with the study procedures.
 - The subject has a permanent caregiver and is willing to attend all study visits for Parts A and B.
 - The subject has provided full written informed consent prior to the performance of any protocol specific procedure or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative.
 - The caregiver has provided his / her written consent prior to the performance of any protocol specific procedure.
 Exclusion Criteria :.
 - In the opinion of the investigator, following review of CT/MRI scans in the past 12 months and completion of neurological review there could be other probable causes of dementia.
 - History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study or current depression ( a score of  >= 8 on the Cornell Scale for Depression in Dementia ) or subjects with other psychiatric features in their AD which would in the opinion of the investigator, would increase risk to safety.
 - History of significant sleep disturbance, for example, when it is associated with nocturnal wandering, nocturnal confusion / disorientation / agitation, which in the opinion of the investigator, may increase safety risk.
 - History or presence of known or suspected seizures, unexplained significant loss of consciousness within last 6 months. Subjects who had febrile seizures in childhood may be included if these ceased by age 10 and they have had no other type of seizure in their medical history and have not been on anti-epileptic medications.
 - History or presence of significant cardiovascular, gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.
 - History of alcohol or other substance abuse, according to the Diagnostic and Statistical Manual of Mental Disorders - Substance related disorders ( DSM-IV ) criteria.
 - Clinically significant abnormalities in laboratory tests, including subjects with active liver disease or uncontrolled thyroid disease.
 - Uncontrolled hypertension with systolic BP  >= 160 and/or diastolic  >= 95 mmHg. Subjects with controlled hypertension with systolic BP < 160 mmHg and diastolic  < 95 mmHg for at least 4 weeks are acceptable.
 - Systolic BP  < 100 mmHg and/or diastolic  < 60 mmHg.
 - Subjects with ECG criteria outside ranges specified in the protocol.
 - History of hypersensitivity to GSK239512 or its excipients.
 - Treatment with cholinesterase inhibitors, ( including Tacrine ), memantine or selegiline within the previous month. No patients with AD who are already on these medications at the time of screening will be recruited, as it would be unethical to withdraw these medications for study participation. Only AD subjects who are not yet on these medications or who have withdrawn from these medications for other reasons previously, may be enrolled into this study.
 - Subjects who are currently taking or who have taken in the last month anti-psychotic drugs ( typical or atypical dopaminergic antagonists or modulators ) or mood stabilization drugs ( including SSRI, DNRI, SNRI, MAO inhibitors, tricyclic antidepressants, lithium, valproate, carbamazepine ).
 - Subjects who are currently taking Pgp inhibitors or any CYP3A4 inhibitors.
 - Subjects on chronic sedative medications (>= 4 days per week for the past 4 weeks ).
 - Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.
 - Has received any other investigational treatment in the previous 3 months.

>>NCT00000176
Inclusion Criteria :.
 - Healthy women 65 or older with a family history of memory problems not currently on estrogen.
 Exclusion Criteria :.
 - Significant neurological impairment.
 - Current estrogen use.
 - History of breast cancer.

>>NCT02256306
Inclusion Criteria :.
 - Diagnosis of probable Alzheimer's disease ( NIA-AA criteria ).
 - Mini-Mental State Examination ( MMSE ) score 12 - 24.
 - Availability of a study partner who knows the patient well and is willing to accompany the patient to all trial visits and to participate in questionnaires.
 Exclusion Criteria :.
 - Pregnancy or unwilling to use adequate birth control method for duration of and 6 months beyond study participation.
 - Positive for Hepatitis B, Hepatitis C or HIV at screening.
 - Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study.
 - Related to medical history :.
 - Stroke.
 - Anaphylaxis.
 - Prior adverse reaction to any human blood product.
 - Any history of a blood coagulation disorder or hypercoagulability.
 - Congestive heart failure.
 - Renal failure.
 - Prior intolerance to intravenous fluids.
 - Recent history of uncontrolled atrial fibrillation.
 - IgA deficiency ( by history ).
 - Related to medications or other treatments :.
 - Any concurrent use of an anticoagulant therapy. Antiplatelet drugs ( e.g., aspirin or clopidogrel ) are acceptable.
 - Initiation or change in the dosage of a cholinesterase inhibitor or memantine during the trial. A participant already on a cholinesterase inhibitor or memantine must be on a stable dose for at least one month prior to Screening.
 - Concurrent participation in another treatment trial for Alzheimer's disease. If there was prior participation, the last dose of the investigational agent must have been at least 6 months prior to Screening.
 - Treatment with any human blood product, including intravenous immunoglobulin, during the 6 months prior to Screening or during the trial.
 - Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics, long-acting opioids or other medications that, in the investigator's opinion, interfere with cognition. Intermittent treatment with short-acting benzodiazepines or atypical antipsychotics may be permitted, provided that no dose is administered within the 72 hours preceding any cognitive assessment.
 - Related to magnetic resonance imaging :.
Claustrophobia.
Any metallic surgical implant, like a pacemaker or clip that is incompatible with 3T MRI. Certain metallic implants like joint replacements may be permitted, provided that specific manufacturer specifications are available and that the device is known to be safe for 3T MRI.
